Background. Endemic hepatitis B virus (HBV) infection is a serious health problem in China. Hepatitis B vaccination of infants was introduced in 1992 and was progressively expanded during the subsequent 15 years.
transmission in China. Therefore, China has made strong efforts to establish universal infant immunization. The recommended schedule involves administration of the first dose within 24 h after birth and administration of subsequent doses at ages 1 and 6 months-a schedule shown to be 70%-95% effective in preventing transmission from mother to infant [6, 7] . In 1992, the Ministry of Health recommended routine immunization with the hepatitis B vaccine for routine immunization of infants. At this time, parents could be charged for the cost of hepatitis B vaccine and its administration. Data from national Expanded Programme on Immunization reviews showed that the rate of immunization coverage with the 3-dose series was 70.7% for children born in 1997 and was highest in urban and eastern areas [8] . In 2002, China fully integrated hepatitis B vaccine into the routine immunization program, providing free vaccine, although parents could still be charged a user fee. A collaborative project between the China Ministry of Health and the Global Alliance for Vaccines and Immunization assured that free vaccine would be available for all children born in poorer western provinces and impoverished areas of the central provinces beginning in 2003 [9] . In 2004, a review by the National Expanded Programme on Immunization reported that, for children born during [2001] [2002] [2003] , the rate of 3-dose vaccine coverage reached 85.5% nationally; the rate was 94.1% in the eastern provinces but only 68.0% in western provinces [10] . In 2005, the State Council issued the "Regulation on Vaccine Circulation and Immunization Management," which eliminated all vaccination-associated charges, so that infants born after 1 June 2005 would be provided with hepatitis B vaccine for free [11] . In 2006, the Chinese government conducted a national serosurvey to evaluate the progress in the prevention of hepatitis B. This article describes the immunization coverage for children who were born after hepatitis B vaccine had been integrated into routine immunization, identifies risk factors for underimmunization, and evaluates the impact of hepatitis B vaccination on the seroprevalence of HBV markers among children born during 1992-2005.
METHODS
Study population. The target population was children born during the period 1 January 1992 through 31 December 2005 in each of 160 national Disease Surveillance Points (DSP) in 31 provinces, which were selected by the Chinese Center for Disease Control and Prevention (CDC) to be representative of the population of China. Each DSP consists of 1 county; in total, 73 million persons live in these counties, with a birth rate of 12.09 births per thousand inhabitants. Demographic characteristics and economic conditions in these points are not statistically different from those for whole country [12] [13] [14] . These sites were divided into 6 major regional groups (eastern urban, eastern rural, central urban, central rural, western urban, and western rural) for sampling. Western provinces included Chongqing, Gansu, Guangxi, Guizhou, Inner Mongolia, Ningxia, Qinghai, Shaanxi, Sichuan, Tibet, Yunnan, and Xinjiang. Central provinces included Anhui, Hainan, Hebei, Heilongjiang, Henan, Hubei, Hunan, Jiangxi, Jilin, and Shanxi. Eastern provinces included Beijing, Fujian, Guangdong, Jiangsu, Liaoning, Shandong, Shanghai, Tianjin, and Zhejiang. Children aged 1-14 years and adults aged 15-59 years who had resided in the DSP for 16 months at the survey visit were selected for the study; the complete selection methods are described elsewhere [15] .
Sampling method. With use of the expected prevalences of HBsAg for different age groups in the study (1% for age 1-4 years, 4% for age 5-14 years, and 9% for age 15-59 years), the desired sample size was 79,129 children, including 15,213 children aged !5 years and 23,416 children aged 5-14 years.
First, 369 townships were identified from 160 counties (1-4 townships per county) by simple random selection; second, one village was randomly selected from each township; and third, the populations of children aged 1-4 and 5-14 years were enumerated and selected on the basis of systematic interval from a list of village residents. Average sampling proportions for each age group at village were 1:1 for children aged !5 years and 1:7 for children aged 5-14 years.
Investigation. A house-to-house investigation was completed by trained staff on the basis of the sampled name list. Basic information, including sex, birth date, ethnicity, place of birth, and immunization history, was compiled through parent interview. Immunization status was recorded from the child's home immunization certificate or, if not available, by a review of the child's immunization card at the township immunization clinic; if neither was available, the village doctor's registry was reviewed. Otherwise, the immunization information was recorded as unvaccinated or unknown. Full vaccination was defined as receipt of 3 doses of hepatitis B vaccine within 12 months, as documented by any immunization record. Timely birth-dose coverage was defined as receipt of the first dose of hepatitis B vaccine within 1 day after birth.
Specimen collection. Blood samples were obtained from each study participant (4 mL for children aged у2 years and 2 mL for children aged !2 years). Serum was separated in county laboratories, transported, and stored at Ϫ20ЊC, initially at provincial laboratories and subsequently at the National Hepatitis Laboratory, Chinese CDC (Beijing) .
Laboratory testing. All serum specimens were tested in the National Hepatitis Laboratory, Institute for Viral Disease Control and Prevention (IVDC) at the Chinese CDC. A detailed laboratory testing protocol was used that included retesting of Data analysis. All data were double-inputted using EPI Data software, version 3.02 (The EpiData Association), and were checked for consistency. After we verifying the accuracy of the data set, it was analyzed at the Chinese CDC with SAS software, version 9.13 (SAS Institute).
Appropriate sampling weights were constructed for national sample data set. The weight for person i can be expressed as follows:
where is the reciprocal of the inclusion probability of town-
is the reciprocal of the conditional inclusion probw jFk ability of village within the selected township k; is the j w iFk,j reciprocal of the conditional inclusion probability of person i within the selected village ; and is an adjustment factor j w adj for person i such that the sum of the weights equals the actual size of the Chinese population.
The Taylor series linearization methods were applied for variance estimation. We used survey freq procedure in SAS software for computation. The weighted prevalence rates of hepatitis B vaccination and HBV biomarkers include the point estimates and their estimated 95% confidence intervals [16] [17] [18] [19] [20] . Multivariable logistic regression (forward method) was used to identify the predictors of a high risk of undervaccination. Vaccine efficacy was calculated using the formula HBV infection among unvaccinated children, and AR v is the prevalence among vaccinated children. Quality control. National specialist groups were convened to guide statistical design, epidemiological investigation, laboratory testing and logistic services, training, and data analysis. Two field pilots were conducted before the survey. Appropriate visiting time was considered to ensure high response rate. Trained county CDC staff were responsible for administering the questionnaire and for collecting, storing, and transporting the blood specimens.
Ethics issues. The survey was approved by the Chinese CDC Ethics Committee, and all study work was performed in accordance with the national ethics regulations. Study participants were informed of the study purpose and of their right to keep information confidential.
RESULTS
Characteristics of study population. During the investigation, 87,454 persons (age, 1-59 years) were enumerated; among these, 5376 were excluded because they could not be reached or refused to participate, 82,078 were interviewed, and 82,008 provided blood samples. 
Prevalence of HBV infection among children born during the period 1992-2005, by year. The weighted prevalence of
HBsAg among children born during 1992-2005 was 2.1%, with the highest prevalence noted in the oldest children; the prevalence decreased steadily with decreasing age (table 3) . Among children born in 1992, the prevalence of HBsAg was 5.5%, decreasing to 1.8% among children born during the period 1993-1998. Among children born after 1998, the prevalence of HBsAg was ∼1%. The prevalence of anti-HBc also decreased monotonically with age, from 16.5% in the oldest children to 3.3% in the youngest children children. Conversely, the weighted prevalence of anti-HBs decreased steadily with earlier birth year, reaching a plateau of ∼55% in children born before 2002 (table 3) .
Weighted prevalence of HBsAg and other HBV markers and immunization history. The weighted prevalence of HBsAg was significantly lower among children who had been fully vaccinated than among unvaccinated children and among those with unknown immunization status. The prevalence of HBsAg among children who received the full 3-dose immunization series and the timely birth dose were 1.0% and 0.7% among children born during 1992-2001 and 2002-2005, respectively (table 4). The prevalence of HBsAg among children who received a birth dose 2-7 days after birth was 0.4%-0.5%, which was lower than the prevalence among children who received a birth dose on time, although the difference was not statistically significant. However, children who received the birth dose after 1 week of age had higher HBsAg prevalences (1.3%-1.8%); this difference was statistically significant for children born during 2002-2005. Among children who had not been immunized, the prevalence of HBsAg was 5.5%-5.6%, which was ∼60% of that observed among children in this age group in the 1992 hepatitis B serosurvey [2] . On the basis of these results, the efficacy of hepatitis B vaccine for fully and on-time immunized infants, compared with nonimmunized infants, is estimated to be 88%. The weighted prevalence of anti-HBs was higher among fully immunized children (63.2% and 74.3% for children born during 1992-2001 and 2002-2005, respectively) than among nonimmunized children (34.8% and 21.1%, respectively) during both time periods. The prevalence of anti-HBc was significantly lower among fully immunized children (3.7%-5.6%) than among nonimmunized children (10.6%-17.8%).
Multivariable regression analysis on risk of low immunization coverage. Multivariable analysis was used to examine risk factors for not being fully immunized for hepatitis B, with vaccination status as the dependent variable and age, sex, ethnicity, type of residence, region, and birthplace as covariates. Risk factors for low 3-dose immunization coverage included being born before 2001; Tibetan, Uigur, and other ethnicity, compared with Han ethnicity; and residence in the western region and a rural location. In addition, the rate of full immunization was lower among children who had been born at home or in other settings than among children who had been born at the hospital (table 5) .
Results for low timely birth dose coverage were almost identical to those for full immunization series, although the odds ratios were higher for most factors. Thus, birth before 2001; Tibetan, Uigur, Zhuang, and other ethnicity; residence in the western region and a rural location; and birth in a township hospital or at home were strong predictors of low timely birth dose (table 5) .
DISCUSSION
Before wide availability of hepatitis B vaccine in China, HBV infection was acquired rapidly by perinatal and infant transmission among children aged 1-4 years, with the prevalence of HBsAg reaching 9.8% and remaining consistently high in older age groups. Among the global deaths attributed to hepatitis B, ∼40% occur in China [21] . Therefore, control of hepatitis B is among the highest priorities in China. Policies currently being implemented to control hepatitis B include universal infant immunization, HBsAg screening of blood for transfusion, control of blood exposure in medical settings, and management and treatment of HBV-infected persons [10] . Vaccination is considered the most cost-effective way to control hepatitis B, and immunization of newborns is necessary to prevent perinatal HBV transmission [9, 22] . Hepatitis B vaccine was fully integrated into the National Immunization Program in 2002, and since 2005, vaccination for all infants has been provided for free, providing equal opportunity for all socioeconomic classes. Since 2002, multiple approaches have been implemented to increase the number of children who receive timely birth doses, with strongest emphasis on increasing the proportion of births in hospitals, building collaboration between Maternal Child Health and Expanded Programme on Immunization departments, and assuring timely birth doses for children born in hospitals. Assuring safe childbirth has been a national priority since 2000; in addition to training and to upgrading hospital facilities, the government provides subsidies to pregnant women to deliver in hospitals through national rural health reform cooperation policy, which reduces or eliminates the hospital charges. This has increased the percentage of births that occur in hospitals to 185% nationally. Regular communication between Maternal Child Health and Expanded Programme on Immunization has been mandated by provincial and local health bureaus to ensure collaboration to deliver vaccination. In 2002, national guidelines were established to require obstetrical nurses who deliver babies to administer the birth dose of hepatitis B vaccine р24 h after birth. Because of strong training, systematic record-keeping, and regular monitoring, the policy has been well implemented [23] , with coverage now exceeding 90% in most hospitals. Timely administration of birth doses for children born at home may be provided by village doctors, who coordinate with Maternal Child Health staff and midwives to track pregnancies and to facilitate the availability of hepatitis B vaccine in the village at time of childbirth.
The successful introduction of hepatitis B vaccine into the national immunization program has had a great impact on the prevalence of HBsAg among population aged 1-14 years. The results affirm that universal vaccination of infants contributed directly to the reduction of the HBsAg prevalence; vaccination with a full series and the timely birth dose was 88% effective, compared with the prevalence in unvaccinated children among both recently born and older children. Of interest, nonimmunized children tested in 2006 had lower a prevalence of HBsAg than did children from same age group who were tested in the 1992 serosurvey (5.6% vs. 9.8%) [2] . This is likely associated with several factors: a modest decrease in the HBsAg prevalence among women (age, 15-59 years), from 8.1% in 1992 to 6.7% in 2006; reduced size of families because of the 1-child-per-family policy-and, therefore, the reduced transmission risk among children; improvement of safe injection practices [8, 9] ; and herd immunity resulting from high rates of vaccination.
Hepatitis B vaccination of infants and children has been demonstrated to reduce the prevalence of HBsAg in many different populations that previously experienced high endemicity of HBV infection [24, 25] . Previous studies have shown marked reduction in prevalence in both urban and rural areas of China (e.g., Shanghai, LongAn County, and Beijing), Africa (e.g., the Gambia and Senegal), and all other regions where HBV infection is highly endemic [26] [27] [28] [29] [30] [31] [32] [33] . This study reaffirms the effectiveness of infant vaccination for the national Chinese popu- Reference.
lation and demonstrates the importance of timely birth doses for greatest reduction of risk. Delayed delivery of timely birth dose that occurs within 1 week also appeared to reduce the prevalence of infection among infants. This is reassuring for programs in which challenges remain to achievement of administration of timely birth doses within 24 h. However, this finding is based on observations in a relatively small number of infected infants and will require confirmation in a larger study to be sufficient to consider modification of current hepatitis B vaccine birth dose recommendations. Available controlled trials have revealed that timely administration of the birth dose within 24 h after birth is highly effective for prevention of hepatitis B among children born to highly infectious HBsAg-and hepatitis B e antigen (HBeAg)-positive mothers or those with high HBV DNA, and it is strongly recommended that hepatitis B vaccination programs provide the birth dose within 24 h after birth if possible. Although, in China, there has been a great improvement in infant hepatitis B vaccination coverage and a reduced prevalence of HBsAg among young children, this study shows that certain groups remain at high risk of not receiving timely birth dose or full immunization. Because of uneven economic development among regions, immunization coverage remains low in rural areas and in the western region and among several ethnic minority groups. Finally, children born at home remain at very high risk of not receiving timely birth dose or full immunization. Because a high proportion of women of childbearing age remain HBsAg and HBeAg positive (6.7% are HBsAg positive, 30% of HBsAg-positive women are HBeAg positive), to achieve additional gains in reducing the hepatitis B risk among children, the national program must continue to improve immunization-in particular, timely administration of birth doses-for these high-risk groups [15] . In addition, efforts still need to focus on assuring high timely birth dose coverage (195%) among children born in hospitals. Field studies from China indicate that birth doses are often delayed as a result of false contraindications, including low birth weight (!2500 g), prematurity, and unstable infant condition [23] . Hepatitis B vaccine has been shown to be safe when given to infants of any age, and prematurity and low birth weight should not delay the administration of timely birth doses [34] .
This study has several limitations. First, because the target population was children who lived in a village for 16 months, some floating (migrant) children and children who had been born outside of the birth control plan (i.e., unregistered children) were excluded from the study. Therefore, this study may overestimate immunization coverage. The floating population represents only a small proportion of children in this age group (3%), but the number of unregistered children is not known. Secondly, the efficacy of timely birth dose vaccination may be overestimated, because in urban areas, many pregnant women are screened for HBsAg, and infants born to HBsAg-positive mothers are given not only hepatitis B vaccine but also hepatitis B immune globulin (HBIG) at birth. In this survey, the proportion of infants who were reported by parents to have received HBIG was relatively small (!1%), and exclusion from the analysis did not change the results. One other limitation is that, because all children were tested during 2006, children aged China has made a great achievement in integrating hepatitis B vaccine into routine immunization programs, achieving very high full immunization coverage and timely administration of birth doses. There has been a dramatic reduction in the prevalence of HBsAg among young children. In particular, the collaborative approach to achieve uniform vaccination of infants at birth should serve as a guide to other countries with high HBV endemicity to achieve rapid reduction in perinatal HBV transmission. The prevalence of HBsAg among children aged !7 years is now ∼1%, indicating achievement of the national goal of a 1% HBsAg prevalence among children by 2010 and of the World Health Organization (WHO) Western Pacific Regional Office hepatitis B reduction goal. The Western Pacific Regional Office is the first WHO region to set a time-bound goal of reducing chronic HBV infection rates to !2% among 5-year-old children by 2012. To further reduce the prevalence of HBsAg, to accelerate progress toward additional reductions in hepatitis B transmission, and to assure high levels of protection for the Chinese population, the national program will need to focus its strongest efforts on improving timely birth doses among disadvantaged minority populations; in the western rural areas, where many births still occur at home; and among floating and unregistered children. In addition, China should continue to focus on protecting all children through providing vaccination to previously unvaccinated children aged !5 years and to expanding coverage to all children aged !15 years and to high-risk populations.
